US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday.
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday’s Mid-Day Session
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
This Analyst Boosts Price Target On Satsuma Pharmaceuticals By 200%? Plus UBS Predicts $38 For General Motors
SVB Leerink raised the price target on Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) from $5 to $15. SVB Leerink analyst Marc Goodman upgraded the stock from Market Perform to Outperform. Satsuma Pharmaceuticals shares fell 3.8% to close at $5.36 on Friday.
SVB Leerink Upgrades Satsuma Pharmaceuticals to Outperform, Raises Price Target to $15
SVB Leerink analyst Marc Goodman upgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Market Perform to Outperform and raises the price target from $5 to $15.
This Stock Earns Price Bump, Bullish Pitch On Recent Positive Migraine Drug Data
Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced positive results from the ASCEND open-label, long-term safety trial for STS101 intranasal dry powder dihydroergotamine (DHE)…
HC Wainwright & Co. Maintains Buy on Satsuma Pharmaceuticals, Raises Price Target to $18
HC Wainwright & Co. analyst Oren Livnat maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and raises the price target from $15 to $18.
Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate
Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced favorable safety, tolerability, and efficacy results from its recent analysis of the ongoing STS101 ASCEND…
